ArticleClinical rheumatology2026
Association of transferrin levels with clinical outcomes in ANCA-associated vasculitis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune disease characterized by ANCA production and inflammation of small blood vessels, leading to multi-organ involvement. Given systemic inflammation is a feature of AAV, inflammation related proteins may reflect disease status. Transferrin (Tf), a negative acute phase protein, decreases during inflammation, however, its association with AAV activity and clinical outcomes remains unclear.
methodsA total of 261 participants were included. All data were extracted from the electronic medical records, and follow-up data were recorded over a two-year period.
resultsOur results showed that serum Tf levels were significantly reduced in AAV, especially in patients with active disease compared with those in remission (P < 0.0001). Receiver operating characteristic (ROC) analysis identified Tf cut-off values of 194 mg/dL for discriminating active from remission AAV and 259.5 mg/dL for distinguishing remission AAV from healthy controls (P < 0.0001). Serum Tf levels were significantly correlated with inflammatory markers, renal function parameters, Birmingham vasculitis activity score (BVAS), and iron metabolism indicators. Regarding treatment and prognosis, serum Tf levels were negatively correlated with patients' maximum daily glucocorticoid dose (P = 0.0026). In multivariable Cox regression analysis, serum Tf levels independently predicted two-year mortality risk and disease remission.
conclusionsOur results indicate that serum Tf levels are decreased in patients with AAV and are associated with adverse adverse clinical outcomes. Key Points • Transferrin levels reflect inflammation and disease activity in ANCA-associated vasculitis. • Low transferrin levels indicate poor prognosis in patients with ANCA-associated vasculitis.
Indexed as
Identifiers
41984347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.